NCNuCana plc NCNA · NASDAQ
$1.08 -2.27% (-$0.03)
- Market cap
- £4.90M
- Enterprise value
- -£13.8M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -56.6%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.31
- Free float
- 94.1%
About the company
NuCana is a biotechnology company focused on developing new cancer treatments. The company utilizes its proprietary ProTide technology to create more effective versions of existing chemotherapy drugs, aiming to enhance their efficacy while reducing side effects. NuCana focuses on improving treatment outcomes for patients with various types of cancer, including pancreatic, liver, and ovarian cancers.
Sector
Healthcare
Industry
Biotechnology
CEO
Hugh Stephen Griffith
Employees
11
Headquarters
Edinburgh
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: It beat profit estimates 7 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: £19.4M against £667.9K.
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number